FindMyKOL

Narender Annapureddy, MD

Basic profile

Vanderbilt University

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNashville, TN · SoutheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Narender Annapureddy is a Rheumatology/Immunology physician affiliated with Vanderbilt University. OpenAlex indexes 70 publications with 878 citations (h-index 21).

Overview

Scholarship

indexed output and impact (OpenAlex)
70publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

878citations

Citations across these publications.

21h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • GlaxoSmithKline, LLC.
    Program year20251 payment
    $650
  • AstraZeneca Pharmaceuticals LP
    Program year20251 payment
    $96
  • GlaxoSmithKline, LLC.
    Program year20244 payments
    $5,481
All 11 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    42.7%
    TNF inhibitor18%
    Humira(Cf) Pen59%Enbrel Sureclick41%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor10.5%
    Methotrexate100%
    Part D≥24 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    15.4%
    Corticosteroid14%
    Prednisone100%
    Part D≥36 patients
    Antidiarrheal microorganisms1.5%
    Folic Acid100%
    Part D<11 patients
  • Musculoskeletal

    13.4%
    Nonsteroidal Anti-inflammatory Drug6.9%
    Diclofenac Sodium71%Nabumetone29%
    Part D<11 patients
    Xanthine oxidase inhibitor4.9%
    Allopurinol100%
    Part D≥15 patients

    + 1 more class in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”